{
    "nct_id": "NCT04396808",
    "official_title": "Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR): A Randomized Multi-center Study for Men With Newly Diagnosed Favorable Risk Prostate Cancer",
    "inclusion_criteria": "* Prostate cancer patients who have undergone diagnostic prostate biopsy in the past 9 months.\n* Prostate biopsy tumor tissue (FFPR block) available for processing\n* Age 18 years or older\n* PSA <20 ng/ml\n* Grade Group (GG) 1 cancer with > 2 biopsy cores involved with cancer OR GG2 cancer\n* Ability to understand and the willingness to sign a written informed consent. A subject's legally acceptable representative may sign the consent form.\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Clinical (on digital rectal exam) or radiographic evidence (if MRI performed) of T3 disease\n* Nodal or metastatic prostate cancer (if staging imaging performed)\n* Prior prostate cancer treatment, including prostatectomy, radiation therapy, or hormone therapy.\n* Prior prostate gene expression classier testing",
    "miscellaneous_criteria": ""
}